1-9 of 9
Ryan D. Cassaday
Close
Sort by
Journal Articles

Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL

Yaqi Zhao, A. Douglas Laird, Kathryn G. Roberts, Rolla Yafawi, Hagop Kantarjian, Daniel J. DeAngelo, Matthias Stelljes, Michaela Liedtke, Wendy Stock, Nicola Gökbuget, Susan O’Brien, Elias Jabbour, Ryan D. Cassaday, Melanie R. Loyd, Scott Olsen, Geoffrey Neale, Xueli Liu, Erik Vandendries, Anjali Advani, Charles G. Mullighan
Journal: Blood Advances
Blood Adv (2024) 8 (12): 3226–3236.
https://doi.org/10.1182/bloodadvances.2023012430
Published: 2024
Includes: Supplemental data
Journal Articles

Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic

Clinical Trials & Observations
Rahul Banerjee, Christina Poh, Alexandre V. Hirayama, Jordan Gauthier, Ryan D. Cassaday, Mazyar Shadman, Andrew J. Cowan, Brian G. Till, Damian J. Green, Hans-Peter Kiem, Ajay K. Gopal, David G. Maloney
Journal: Blood Advances
Blood Adv (2024) 8 (4): 895–898.
https://doi.org/10.1182/bloodadvances.2023012336
Published: 2024
Journal Articles

Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma

Alexandre V. Hirayama, Erik L. Kimble, Jocelyn H. Wright, Salvatore Fiorenza, Jordan Gauthier, Jenna M. Voutsinas, Qian Wu, Cecilia C. S. Yeung, Nicolas Gazeau, Barbara S. Pender, Delaney R. Kirchmeier, Aiko Torkelson, Abigail N. Chutnik, Ryan D. Cassaday, Aude G. Chapuis, Damian J. Green, Hans-Peter Kiem, Filippo Milano, Mazyar Shadman, Brian G. Till, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle
Journal: Blood Advances
Blood Adv (2024) 8 (2): 453–467.
https://doi.org/10.1182/bloodadvances.2023011287
Published: 2024
Includes: Supplemental data
Journal Articles

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL

Clinical Trials & Observations
Emily C. Liang, Aya Albittar, Jennifer J. Huang, Alexandre V. Hirayama, Erik L. Kimble, Andrew J. Portuguese, Aude Chapuis, Mazyar Shadman, Brian G. Till, Ryan D. Cassaday, Filippo Milano, Hans-Peter Kiem, Stanley R. Riddell, Cameron J. Turtle, David G. Maloney, Jordan Gauthier
Journal: Blood Advances
Blood Adv (2023) 7 (22): 6990–7005.
https://doi.org/10.1182/bloodadvances.2023011399
Published: 2023
Includes: Supplemental data
Journal Articles

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML

Clinical Trials & Observations
Anna B. Halpern, Eduardo Rodríguez-Arbolí, Megan Othus, Kelsey-Leigh A. Garcia, Mary-Elizabeth M. Percival, Ryan D. Cassaday, Vivian G. Oehler, Pamela S. Becker, Jacob S. Appelbaum, Janis L. Abkowitz, Johnnie J. Orozco, Siobán B. Keel, Paul C. Hendrie, Bart L. Scott, M. Cristina Ghiuzeli, Elihu H. Estey, Roland B. Walter
Journal: Blood Advances
Blood Adv (2023) 7 (17): 4950–4961.
https://doi.org/10.1182/bloodadvances.2023010392
Published: 2023
Journal Articles

Megadose 90 Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma

Clinical Trials & Observations
Victor A. Chow, Ryan D. Cassaday, Theodore A. Gooley, Stephen D. Smith, Brenda M. Sandmaier, Damian J. Green, Johnnie J. Orozco, Sherilyn A. Tuazon, Manuela Matesan, Darrell R. Fisher, David G. Maloney, Oliver W. Press, Ajay K. Gopal
Journal: Blood Advances
Blood Adv (2021) 6 (1): 37–45.
https://doi.org/10.1182/bloodadvances.2021005056
Published: 2021
Journal Articles

Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia

Clinical Trials & Observations
Ryan D. Cassaday, Kelsey-Leigh A. Garcia, Jonathan R. Fromm, Mary-Elizabeth M. Percival, Cameron J. Turtle, Paul T. Nghiem, Phillip A. Stevenson, Elihu H. Estey
Journal: Blood Advances
Blood Adv (2020) 4 (14): 3239–3245.
https://doi.org/10.1182/bloodadvances.2020002403
Published: 2020
Includes: Supplemental data
Journal Articles

Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes

Clinical Trials & Observations
Caner Saygin, Ashwin Kishtagari, Ryan D. Cassaday, Natalie Reizine, Ilana Yurkiewicz, Michaela Liedtke, Wendy Stock, Richard A. Larson, Ross L. Levine, Martin S. Tallman, Jae H. Park, Cassandra Kerr, Bartlomiej Przychodzen, Mikkael A. Sekeres, Matt E. Kalaycio, Hetty E. Carraway, Betty K. Hamilton, Ronald Sobecks, Aaron Gerds, Sudipto Mukherjee, Aziz Nazha, Jaroslaw P. Maciejewski, Anjali S. Advani
Journal: Blood Advances
Blood Adv (2019) 3 (24): 4228–4237.
https://doi.org/10.1182/bloodadvances.2019000925
Published: 2019
Includes: Supplemental data
Journal Articles

Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy

Mazyar Shadman, Jordan Gauthier, Kevin A. Hay, Jenna M. Voutsinas, Filippo Milano, Ang Li, Alexandre V. Hirayama, Mohamed L. Sorror, Sindhu Cherian, Xueyan Chen, Ryan D. Cassaday, Brian G. Till, Ajay K. Gopal, Brenda M. Sandmaier, David G. Maloney, Cameron J. Turtle
Journal: Blood Advances
Blood Adv (2019) 3 (20): 3062–3069.
https://doi.org/10.1182/bloodadvances.2019000593
Published: 2019